Literature DB >> 15555001

A prospective comparative study of ASCA and pANCA in Chinese and Caucasian IBD patients.

Ian Craig Lawrance1, Kevin Murray, Anne Hall, Joseph J Y Sung, Rupert Leong.   

Abstract

BACKGROUND: Inflammatory bowel disease manifests throughout all ethnic groups. Antisaccharomyces cerevisiae (ASCA) and antineutrophil cytoplasmic antibodies (pANCA) can aid in the differentiation between Crohn's disease (CD) and ulcerative colitis (UC), but their sensitivity may vary between races.
OBJECTIVES: This study compared the sensitivity, specificity, and positive and negative predictive values (PPV, NPV) of pANCA and ASCA between Chinese and Caucasian IBD populations and identified disease subtype associations.
RESULTS: Three hundred patients were prospectively recruited from Caucasian and Chinese populations (CD, n = 50, UC, n = 50, controls, n = 50 each). pANCA detection was greater in Caucasian than Chinese UC patients (p= 0.046). ASCA IgG detection was similar, but IgA was lower in Chinese CD patients (p < 0.001). Differentiation between UC and CD (+ve pANCA/-ve ASCA) demonstrated a PPV of 92% in isolated colonic disease. Logistic regression in CD identified positive pANCA had a lower association with ileal (OR = 6.8, p= 0.0067) and complicated disease (OR = 5.5, p= 0.015). Caucasian CD patients with positive ASCA IgA/IgG had a greater association with ileal (OR = 6.7, p= 0.022) or complicated disease (OR = 9.4, p= 0.0073) and in Chinese CD patients positive ASCA IgA/IgG was associated with isolated ileal disease (OR = 16.8, p= 0.032). Linear regression demonstrated that higher ASCA titers predicted complicated CD and isolated ileal disease.
CONCLUSIONS: This study identified that pANCA is more sensitive in Caucasian than Chinese UC and that ASCA IgA has a low yield in Chinese CD. pANCA and ASCA are useful for differentiating between UC and CD in both populations, and ASCA IgG and IgA titers have potential use in determining the risk of developing complicated CD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15555001     DOI: 10.1111/j.1572-0241.2004.40486.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  18 in total

1.  Diagnostic role and clinical association of ASCA and ANCA in Brazilian patients with inflammatory bowel disease.

Authors:  Renato Mitsunori Nisihara; Wilson Beleski de Carvalho; Shirley Ramos da Rosa Utiyama; Heda Amarante; Márcia Luiza Baptista
Journal:  Dig Dis Sci       Date:  2009-10-14       Impact factor: 3.199

Review 2.  Noninvasive methods in evaluation of inflammatory bowel disease: where do we stand now? An update.

Authors:  Cansel Turkay; Benan Kasapoglu
Journal:  Clinics (Sao Paulo)       Date:  2010-02       Impact factor: 2.365

3.  Inflammatory bowel disease serology in Asia and the West.

Authors:  Lani Prideaux; Michael A Kamm; Peter De Cruz; Daniel R van Langenberg; Siew C Ng; Iris Dotan
Journal:  World J Gastroenterol       Date:  2013-10-07       Impact factor: 5.742

4.  Assessing inflammatory bowel disease-associated antibodies in Caucasian and First Nations cohorts.

Authors:  Charles Noah Bernstein; Hani El-Gabalawy; Michael Sargent; Carol Landers; Patricia Rawsthorne; Brenda Elias; Stephan R Targan
Journal:  Can J Gastroenterol       Date:  2011-05       Impact factor: 3.522

5.  Antibodies against glycoprotein 2 display diagnostic advantages over ASCA in distinguishing CD from intestinal tuberculosis and intestinal Behçet's disease.

Authors:  Shulan Zhang; Jing Luo; Ziyan Wu; Dirk Roggenbuck; Peter Schierack; Dirk Reinhold; Ji Li; Xiaofeng Zeng; Fengchun Zhang; Jiaming Qian; Yongzhe Li
Journal:  Clin Transl Gastroenterol       Date:  2018-02-15       Impact factor: 4.488

Review 6.  Management of inflammatory bowel diseases in Eastern Europe.

Authors:  L Lakatos; P L Lakatos
Journal:  Postgrad Med J       Date:  2006-04       Impact factor: 2.401

7.  Clinical and Phenotypic Differences in Inflammatory Bowel Disease Among Arab and Jewish Children in Israel.

Authors:  Firas Rinawi; Amit Assa; Husam Bashir; Sarit Peleg; Raanan Shamir
Journal:  Dig Dis Sci       Date:  2017-05-25       Impact factor: 3.199

8.  What can we learn from inflammatory bowel disease in developing countries?

Authors:  Sunny H Wong; Siew C Ng
Journal:  Curr Gastroenterol Rep       Date:  2013-03

9.  NOD2 mutations and anti-Saccharomyces cerevisiae antibodies are risk factors for Crohn's disease in African Americans.

Authors:  Themistocles Dassopoulos; Geoffrey C Nguyen; Monica Vladut Talor; Lisa Wu Datta; Kim L Isaacs; James D Lewis; Michael S Gold; John F Valentine; Duane T Smoot; Mary L Harris; Maria Oliva-Hemker; Theodore M Bayless; C Lynne Burek; Steven R Brant
Journal:  Am J Gastroenterol       Date:  2009-10-13       Impact factor: 10.864

10.  Update on Anti-Saccharomyces cerevisiae antibodies, anti-nuclear associated anti-neutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases: results of a multicenter study.

Authors:  S Desplat-Jégo; C Johanet; A Escande; J Goetz; N Fabien; N Olsson; E Ballot; J Sarles; J J Baudon; J C Grimaud; M Veyrac; P Chamouard; R L Humbel
Journal:  World J Gastroenterol       Date:  2007-04-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.